In this context, identifying RAS mutational status is mandatory for all stage IV CRC patients to select KRAS wild-type (wtKRAS) patients that can benefit from anti-EGFR treatment, according to ASCO [12] and ESMO [13] guidelines. Here, KRAS is linked to colorectal carcinoma.